切换至 "中华医学电子期刊资源库"
高级检索
中华危重症医学杂志(电子版)

中华危重症医学杂志(电子版) ›› 2018, Vol. 11 ›› Issue (05) : 310 -315. doi: 10.3877/cma.j.issn.1674-6880.2018.05.006

所属专题： 文献；

论著

微小RNA-142-3p在脓毒症患者血清中的表达及其临床意义
李洁1, 孙敏1, 乐健伟1, 陈红1, 朱建华1,†()   
  1. 1. 315010　浙江宁波，宁波市第一医院重症医学科
  • 收稿日期:2018-03-14 出版日期:2018-10-01
  • 通信作者: 朱建华
  • 基金资助:
    浙江省医药卫生科技计划项目(2017KY585)

Expression of microRNA-142-3p in serum of septic patients and its clinical significance

Jie Li1, Min Sun1, Jianwei Le1, Hong Chen1, Jianhua Zhu1,†()   

  1. 1. Department of Intensive Care Unit, Ningbo First Hospital, Ningbo 315010, China
  • Received:2018-03-14 Published:2018-10-01
  • Corresponding author: Jianhua Zhu
  • About author:
    Corresponding author: Zhu Jianhua, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李洁, 孙敏, 乐健伟, 陈红, 朱建华. 微小RNA-142-3p在脓毒症患者血清中的表达及其临床意义[J/OL]. 中华危重症医学杂志(电子版), 2018, 11(05): 310-315.

Jie Li, Min Sun, Jianwei Le, Hong Chen, Jianhua Zhu. Expression of microRNA-142-3p in serum of septic patients and its clinical significance[J/OL]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2018, 11(05): 310-315.

目的

通过观察脓毒症患者血清中微小RNA-142-3p（miR-142-3p）的表达，探讨其与脓毒症的关系。

方法

选取41例脓毒症患者作为研究对象，同期住院的非脓毒症患者20例作为对照组。采用实时荧光定量PCR检测血清中miR-142-3p的表达，酶联免疫吸附剂测定（ELISA）检测白细胞介素6（IL-6）和IL-10的表达。采用Spearman相关分析miR-142-3p与患者临床特点和实验室指标的相关性，受试者工作特征（ROC）曲线评价miR-142-3p、IL-6、IL-10、C反应蛋白（CRP）、前降钙素原（PCT）、白细胞计数和乳酸表达水平对脓毒症的预测价值。

结果

脓毒症组患者的白细胞计数[（14.4 ± 7.8）× 109/L vs.（8.4 ± 2.1）× 109/L，t = 4.571，P < 0.001]、CRP [（127 ± 80）mg/L vs.（80 ± 45）mg/L，t = 2.436，P= 0.018]、乳酸[（2.3 ± 1.8）mmol/L vs.（1.5 ± 0.6）mmol/L，t = 2.421，P = 0.019]、PCT [5.70（1.49，26.37）μg/L vs. 0.25（0.10，0.63）μg/L，Z= 75.500，P < 0.001]、IL-6 [342.33（64.98，2 618.44）ng/L vs. 14.95（3.21，54.51）ng/L，Z = 84.000，P < 0.001]、IL-10 [23.16（6.19，85.56）ng/L vs. 2.75（1.39，5.36）ng/L，Z = 198.500，P = 0.001]和miR-142-3p [95.74（23.19，278.23）vs. 25.64（18.59，56.05），Z = 222.000，P = 0.004]均显著高于对照组。miR-142-3p与乳酸、IL-6、PCT均呈正相关（r = 0.427、0.340、0.309，P = 0.005、0.030、0.049）。根据脓毒症患者28 d生存情况分为存活组（29例）和死亡组（12例）。存活组的急性病生理学与长期健康评价（APACHE）Ⅱ评分[（14 ± 6）分vs.（25 ± 6）分]、序贯性器官衰竭估计（SOFA）评分[（6.0 ± 2.8）分vs.（10.7 ± 3.5）分]和乳酸[（1.6 ± 1.0）mmol/L vs.（3.8 ± 2.6）mmol/L]水平均显著低于死亡组（t = 5.406、4.482、2.835，P均< 0.05）。ROC曲线分析结果显示，miR-142-3p [曲线下面积（AUC）= 0.729，95%CI（0.602，0.856），P = 0.004]、IL-6 [AUC = 0.898，95%CI（0.820，0.975），P < 0.001]、CRP [AUC = 0.698，95%CI（0.566，0.831），P = 0.013]、PCT [AUC = 0.908，95%CI（0.835，0.981），P < 0.001]、IL-10 [AUC = 0.758，95%CI（（0.631，0.885），P = 0.001]和白细胞计数[AUC = 0.776，95%CI（0.659，0.893），P = 0.001]对脓毒症均有预测价值。

结论

脓毒症患者血清中miR-142-3p的表达升高，且与乳酸、IL-6、PCT呈正相关，其在脓毒症发生发展中可能发挥着重要作用。

关键词: 脓毒症, 微小RNA-142-3p, 血清
Objective

To observe the expression of serum microRNA-142-3p (miR-142-3p) in septic patients and to explore its relationship with sepsis.

Methods

Forty-one patients with sepsis were selected as study subjects, and 20 non-septic patients hospitalized in the same period as the control group. The expression of serum miR-142-3p was detected by real-time quantitative PCR, and levels of interleukin-6 (IL-6) and IL-10 were detected by enzyme-linked immunosorbent assay (ELISA). The relationship between miR-142-3p and septic patients' clinical characteristics and laboratory indexes was analyzed by Spearman correlation analysis. In the same time, the predictive value of miR-142-3p, IL-6, IL-10, C-reactive protein (CRP), procalcitonin (PCT), white blood cell count and lactic acid on sepsis was evaluated by the receiver operating characteristic (ROC) curve.

Results

The white blood cell count [(14.4 ± 7.8) × 109/L vs. (8.4 ± 2.1) × 109/L, t = 4.571, P < 0.001], CRP [(127 ± 80) mg/L vs. (80 ± 45) mg/L, t = 2.436, P = 0.018], lactic acid [(2.3 ± 1.8) mmol/L vs. (1.5 ± 0.6) mmol/L, t = 2.421, P = 0.019], PCT [5.70 (1.49, 26.37) μg/L vs. 0.25 (0.10, 0.63) μg/L, Z = 75.500, P < 0.001], IL-6 [342.33 (64.98, 2 618.44) ng/L vs. 14.95 (3.21, 54.51) ng/L, Z = 84.000, P < 0.001], IL-10 [23.16 (6.19, 85.56) ng/L vs. 2.75 (1.39, 5.36) ng/L, Z = 198.500, P = 0.001] and miR-142-3p [95.74 (23.19, 278.23) vs. 25.64 (18.59, 56.05), Z = 222.000, P = 0.004] were significantly higher in the sepsis group than in control group. MiR-142-3p was positively correlated with lactic acid, IL-6 and PCT (r = 0.427, 0.340, 0.309; P = 0.005, 0.030, 0.049). Patients with sepsis were divided into the survival group (29 cases) and death group (12 cases) according to their survival conditions on 28 days. The scores of acute physiology and chronic health evaluation (APACHE) Ⅱ [(14 ± 6) vs. (25 ± 6)] and sequential organ failure assessment (SOFA) [(6.0 ± 2.8) vs. (10.7 ± 3.5)], and lactic acid expression [(1.6 ± 1.0) mmol/L vs. (3.8 ± 2.6) mmol/L] in the survival group were significantly lower than those in the death group (t = 5.406, 4.482, 2.835; all P < 0.05). ROC curve analysis showed that miR-142-3p [area under the curve (AUC) = 0.729, 95%CI (0.602, 0.856), P = 0.004], IL-6 [AUC = 0.898, 95%CI (0.820, 0.975), P < 0.001], CRP [AUC = 0.698, 95%CI (0.566, 0.831), P = 0.013], PCT [AUC = 0.908, 95%CI (0.835, 0.981), P < 0.001], IL-10 [AUC = 0.758, 95%CI (0.631, 0.885), P = 0.001)] and white blood cell count [AUC = 0.776, 95%CI (0.659, 0.893), P = 0.001)] have predictive value for sepsis.

Conclusion

The expression of serum miR-142-3p in septic patients increases, and it is positively related with lactic acid, IL-6 and PCT, which may play an important role in the development of sepsis.

Key words: Sepsis, MicroRNA-142-3p, Serum
表1 脓毒症组和对照组患者一般资料及实验室指标比较（ ± s）
组别 例数 年龄（岁） 性别比（例，男/女） APACHEⅡ评分（分） SOFA评分（分） 白细胞计数(× 109/L) CRP(mg/L) 乳酸(mmol/L)
对照组 20 60 ± 17 12/8 15 ± 3 6.1 ± 1.5 8.4 ± 2.1 80 ± 45 1.5 ± 0.6
脓毒症组 41 59 ± 18 19/22 17 ± 8 7.4 ± 3.6 14.4 ± 7.8 127 ± 80 2.3 ± 1.8
t/χ2/Z值 ? 0.286 1.003 1.148 1.952 4.571 2.436 2.421
P值 ? 0.776 0.316 0.256 0.056 < 0.001 0.018 0.019
组别 例数 PCT [μg/L,M(P25,P75)] IL-6 [ng/L,M(P25,P75)] IL-10[ng/L,M(P25,P75)] miR-142-3p[M(P25,P75)]
对照组 20 0.25(0.10,0.63) 14.95(3.21,54.51) 2.75(1.39,5.36) 25.64(18.59,56.05)
脓毒症组 41 5.70(1.49,26.37) 342.33(64.98,2 618.44) 23.16(6.19,85.56) 95.74(23.19,278.23)
t/χ2/Z值 ? 75.500 84.000 198.500 222.000
P值 ? < 0.001 < 0.001 0.001 0.004
表2 存活组与死亡组脓毒症患者一般资料及实验室指标比较（ ± s）
组别 例数 年龄（岁） 性别比（例，男/女） APACHEⅡ评分（分） SOFA评分（分） 白细胞计数(× 109/L) CRP(mg/L) 乳酸(mmol/L)
存活组 29 56 ± 20 11/18 14 ± 6 6.0 ± 2.8 15 ± 8 127 ± 67 1.6 ± 1.0
死亡组 12 67 ± 12 8/4 25 ± 6 10.7 ± 3.5 12 ± 8 127 ± 109 3.8 ± 2.6
t/χ2/Z值 ? 1.910 1.781 5.406 4.482 1.232 0.015 2.835
P值 ? 0.064 0.182 < 0.001 < 0.001 0.225 0.998 0.015
组别 例数 PCT [μg/L,M(P25,P75)] IL-6 [ng/L,M(P25,P75)] IL-10[ng/L,M(P25,P75)] miR-142-3p[M(P25,P75)]
存活组 29 5.60(0.70,25.26) 342.33(92.29,2 049.54) 18.95(5.48,77.25) 108.13(27.91,351.32)
死亡组 12 9.78(2.72,29.93) 607.15(53.48,4 333.21) 36.52(5.98,281.55) 83.40(17.20,268.54)
t/χ2/Z值 ? 206.500 192.500 204.500 162.000
P值 ? 0.352 0.596 0.382 0.731
表3 miR-142-3p、IL-6、CRP、PCT、IL-10、白细胞计数和乳酸表达水平对脓毒症预测价值的ROC曲线分析
指标 A,C 95%CI 标准误 敏感度(%) 特异度(%) P值
miR-142-3p 0.729 0.602 ~ 0.856 0.065 68.3 70.0 0.004
IL-6(ng/L) 0.898 0.820 ~ 0.975 0.039 78.0 85.0 < 0.001
CRP(mg/L) 0.698 0.566 ~ 0.831 0.068 78.0 45.0 0.013
PCT(μg/L) 0.908 0.835 ~ 0.981 0.037 82.9 95.0 < 0.001
IL-10(ng/L) 0.758 0.631 ~ 0.885 0.065 78.0 75.0 0.001
白细胞计数(× 109/L) 0.776 0.659 ~ 0.893 0.060 73.2 70.0 0.001
乳酸(mmol/L) 0.598 0.454 ~ 0.741 0.073 51.2 60.0 0.219
1
Singer M,Deutschman CS,Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. Jama, 2016, 315(8): 801-810.
2
顾勤,陈鸣. 脓毒症的早期识别与规范治疗[J]. 中华急诊医学杂志, 2013, 22(2): 126-129.
3
Hawiger J,Veach RA,Zienkiewicz J. New paradigms in sepsis: from prevention to protection of failing microcirculation[J]. J Thromb Haemost, 2015, 13(10): 1743-1756.
4
黄颖,寿松涛,王军, 等. 脓毒症与免疫细胞凋亡相关研究进展[J/CD]. 中华危重症医学杂志（电子版）, 2017, 10(4): 270-273.
5
Boran OF,Yazar FM,Boran M, et al. The preseptic period and inflammatory markers in the prediction of the course of sepsis[J]. Med Sci Monit, 2018(24): 3531-3539.
6
Feng M,Sun T,Zhao Y, et al. Detection of serum interleukin-6/ 10 / 18 levels in sepsis and its clinical significance[J]. J Clin Lab Anal, 2016, 30(6): 1037-1043.
7
Filho RR,Rocha LL,Corrêa TD, et al. Blood lactate levels cutoff and mortality prediction in sepsis-time for a reappraisal? a retrospective cohort study[J]. Shock, 2016, 46(5): 480-485.
8
Kingsley SMK,Bhat BV. Role of microRNAs in sepsis[J]. Inflammation Research, 2017, 66(7): 553-569.
9
Huang HC,Yu HR,Hsu TY, et al. MicroRNA-142-3p and let-7g negatively regulates augmented IL-6 production in neonatal polymorphonuclear leukocytes[J]. Int J Biol Sci, 2017, 13(6): 690-700.
10
Risoe PK,Ryg U,Wang YY, et al. Cecal ligation and puncture sepsis is associated with attenuated expression of adenylyl cyclase 9 and increased miR142-3p[J]. Shock, 2011, 36(4): 390-395.
11
Sun Y,Varambally S,Maher CA, et al. Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality[J]. Blood, 2011, 117(23): 6172-6183.
12
Yuan Z,Luo G,Li X, et al. PPARgamma inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo[J]. Cell Signal, 2016, 28(3): 158-164.
13
Maley JH,Mikkelsen ME. Short-term gains with long-term consequences: the evolving story of sepsis survivorship[J]. Clin Chest Med, 2016, 37(2): 367-380.
14
Angus DC,Linde-Zwirble WT,Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med, 2001, 29(7): 1303-1310.
15
Martin GS,Mannino DM,Moss M. The effect of age on the development and outcome of adult sepsis[J]. Crit Care Med, 2006, 34(1): 15-21.
16
Ma H,Wang X,Ha T, et al. MicroRNA-125b prevents cardiac dysfunction in polymicrobial sepsis by targeting TRAF6 mediated NFκB activation and p53 mediated apoptotic signaling[J]. J Infect Dis, 2016, 214(11): 1773-1783.
17
Lv X,Zhang Y,Cui Y, et al. Inhibition of microRNA 155 relieves sepsis induced liver injury through inactivating the JAK / STAT pathway[J]. Mol Med Rep, 2015, 12(4): 6013-6018.
18
Jia P,Wu X,Dai Y, et al. MicroRNA-21 is required for local and remote ischemic preconditioning in multiple organ protection against sepsis[J]. Crit Care Med, 2017,45(7): e703-e710.
19
Ding S,Liang Y,Zhao M, et al. Decreased microRN-A-142-3p/5p expression causes CD4+ T cell activation and B cell hyperstimulation in systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(9): 2953-2963.
20
Wang XS,Gong JN,Yu J, et al. MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia[J]. Blood, 2012, 119(21): 4992-5004.
21
Deng B,Zhang Y,Zhang S, et al. MicroRNA-142-3p inhibits cell proliferation and invasion of cervical cancer cells by targeting FZD7[J]. Tumor Biol, 2015, 36(10): 8065-8073.
22
呼邦传,王宇佳,葛伟东, 等. 脓毒性休克患者左心室舒张功能不全相关因素分析及其预后影响[J/CD]. 中华危重症医学杂志（电子版）, 2017, 10(2): 92-97.
23
郭玉红,戴浩然,刘清泉. 脓毒症急性肾损伤相关因素分析[J]. 世界中医药, 2017, 12(4): 725-727.
24
Mira JC,Gentile LF,Mathias BJ, et al. Sepsis pathophysiology, chronic critical illness, and persistent inflammation-immunosuppression and catabolism syndrome[J]. Crit Care Med, 2017, 45(2): 253-262.
[1] 庄燕, 戴林峰, 张海东, 陈秋华, 聂清芳. 脓毒症患者早期生存影响因素及Cox 风险预测模型构建[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 372-378.
[2] 钱警语, 郑明明. 《2024意大利妇产科学会非侵入性和侵入性产前诊断指南》解读[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 486-492.
[3] 李康虎, 王继伟, 王光远. 腹腔镜下腹股沟疝修补术后并发症及防治进展[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 369-375.
[4] 邓杨, 彭豪, 刘剑文. 腹腔镜疝修补术腹膜前负压引流的效果和长期安全性研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 402-405.
[5] 申亚伟, 黄新, 李万林. 改良医用胶粘合假疝囊技术预防腹腔镜完全腹膜外疝修补术后血清肿的临床研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(04): 410-413.
[6] 张春玉, 陈海云, 肖忠萍, 罗琴, 潘运昌. 血清NT-proBNP 预测肺栓塞心脏功能障碍的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 805-808.
[7] 井发红, 李丽娜, 高婷, 高艳梅, 杨楠, 李卓, 慕玉东. 肺癌立体定向放疗血清SAP 和MMPs 表达及临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 707-713.
[8] 刘思含, 张静. 老年人血清铁与C 反应蛋白的比值及25-羟基维生素D3 与肾功能受损的关系研究[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 268-272.
[9] 陈曦, 吴宗盛, 郑明珠, 邱海波. 胸腺萎缩在脓毒症免疫紊乱中的研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 379-383.
[10] 杨翔, 郭兰骐, 谢剑锋, 邱海波. 转录组学在脓毒症诊疗中的临床研究进展[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 384-388.
[11] 成人脓毒症患者β-内酰胺类抗生素延长输注专家共识编写组. 成人脓毒症患者β-内酰胺类抗生素延长输注专家共识[J/OL]. 中华重症医学电子杂志, 2024, 10(04): 313-324.
[12] 陈惠英, 邱敏珊, 邵汉权. 脓毒症诱发肠黏膜屏障功能损伤的风险因素模型构建与应用效果[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 448-452.
[13] 杨菲, 刘腾飞, 赵志军, 李睿聪, 张颉, 刘妍, 赵珍. 血清维生素水平与分化型甲状腺癌的关联性研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 633-640.
[14] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[15] 傅新露, 李之岳, 卢丹. 妊娠合并结肠癌穿孔致脓毒症休克一例并文献复习[J/OL]. 中华产科急救电子杂志, 2024, 13(04): 227-231.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号